Nölting S, Bechmann N, Taieb D, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43:199–239.

Article  PubMed  Google Scholar 

DuBray La Perle KM, Joradan CD. Endocrine System. Comparative Anatomy and Histology. 2012:211–7.

Mete O, Asa SL, Gill AJ, et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33:90–114.

Article  CAS  PubMed  Google Scholar 

Juhlin CC, Mete O. Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists. 2022.

Asa SL, Ezzat S, Mete O. The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med. 2018;7.

Young WF. Paragangliomas: Clinical Overview. Ann N Y Acad Sci. 2006;1073:21–9. https://doi.org/10.1196/annals.1353.002

Article  CAS  PubMed  Google Scholar 

Van Berkel A, Lenders JWM, Timmers HJLM. Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170. https://doi.org/10.1530/EJE-13-0882

Heesterman BL, de Pont LMH, Verbist BM, et al. Age and Tumor Volume Predict Growth of Carotid and Vagal Body Paragangliomas. J Neurol Surg B Skull Base. 2017;78:497–505. https://doi.org/10.1055/s-0037-1604347 LK - http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=21936331&id=10.1055%2Fs-0037-1604347&atitle=Age+and+Tumor+Volume+Predict+Growth+of+Carotid+and+Vagal+Body+Paragangliomas&stitle=J.+Neurol.+Surg.+Part+B+Skull+Base&title=Journal+of+Neurological+Surgery%2C+Part+B%3A+Skull+Base&volume=78&issue=6&spage=497&epage=505&aulast=Heesterman&aufirst=Berdine+L.&auinit=B.L.&aufull=Heesterman+B.L.&coden=&isbn=&pages=497-505&date=2017&auinit1=B&auinitm=L

Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2014;99:1915–42.

Article  CAS  PubMed  Google Scholar 

Patel D, Phay JE, Yen TWF, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27:1329–37. https://doi.org/10.1245/s10434-020-08220-3

Eisenhofer G, Klink B, Richter S, et al. Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clin Biochem Rev. 2017;69:69–100.

Google Scholar 

Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: Utility of plasma methoxytyramine. Journal of Clinical Endocrinology and Metabolism. 2005;90:2068–75. https://doi.org/10.1210/jc.2004-2025

Article  CAS  PubMed  Google Scholar 

de Bresser CJM, Petri BJ, Braat AJAT, et al. The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([68Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study. Cancers (Basel). 2024;16. https://doi.org/10.3390/cancers16050986

Han S, Suh CH, Woo S, et al. Performance of 68 Ga-DOTA–conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytoma and paraganglioma: A systematic review and metaanalysis. Journal of Nuclear Medicine. 2019;60:369–76. https://doi.org/10.2967/jnumed.118.211706

Article  CAS  PubMed  Google Scholar 

Yang J, Kan Y, Ge BH, et al. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: A meta-analysis. Acta radiol. 2014;55:389–98. https://doi.org/10.1177/0284185113496679

Article  PubMed  Google Scholar 

Chang CA, Pattison DA, Tothill RW, et al. 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: Utility, patterns and heterogeneity. Cancer Imaging. 2016;16:1–12. https://doi.org/10.1186/s40644-016-0084-2

Article  Google Scholar 

Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2020;31:1476–90. https://doi.org/10.1016/j.annonc.2020.08.2099

Article  CAS  PubMed  Google Scholar 

Jha A, Taïeb D, Carrasquillo JA, et al. High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clinical Cancer Research. 2021;27:2989–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. Journal of Clinical Endocrinology and Metabolism. 2021;106:E1937–52.

Article  PubMed  PubMed Central  Google Scholar 

Dahia PLM. Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once! Cancer Cell. 2017;31:159–61.

Article  CAS  PubMed  Google Scholar 

Williams MD, Tischler AS. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas. Head Neck Pathol. 2017;11:88–95. https://doi.org/10.1007/s12105-017-0786-1

Linnoila I, Keiser HR, Steinberg SM, et al. Histopathology of Benign Versus Malignant Sympathoadrenal Paragangliomas: Clinicopathologic Study of 120 Cases Including Unusual Histologic Features. Hum Pathol. 1990;21.

Hescot S, Curras-Freixes M, Deutschbein T, et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): an ENS@T retrospective study. Published Online First: 2019. https://doi.org/10.1210/jc.2018-01968/5304738

Article  Google Scholar 

Castro-Vega LJ, Letouzé E, Burnichon N, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6. https://doi.org/10.1038/ncomms7044

Cheung VKY, Gill AJ, Chou A. Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma. Endocr Pathol. 2018;29:169–75.

Article  PubMed  Google Scholar 

Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405–14. https://doi.org/10.1530/ERC-13-0494

Article  PubMed  Google Scholar 

Thompson LDR. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms A Clinicopathologic and Immunophenotypic Study of 100 Cases. 2002.

Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Archiv. 2019;474:721–34. https://doi.org/10.1007/s00428-019-02553-5

Article  CAS  PubMed  Google Scholar 

Gerdes J, Lemke H, Baisch H, et al. CELL CYCLE ANALYSIS OF A CELL PROLIFERATION-ASSOCIATED HUMAN NUCLEAR ANTIGEN DEFINED BY THE MONOCLONAL ANTIBODY Ki-67’. 1984.

Van Der Harst E, Bruining HA, Bonjer HJ, et al. Proliferative index in phaeochromocytomas: Does it predict the occurrence of metastases? Journal of Pathology. 2000;191:175–80. https://doi.org/10.1002/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z

Article  PubMed  Google Scholar 

Clarke MR, Weyant RJ, Watson CG, et al. Prognostic Markers in Pheochromocytoma. 1998.

August C, August K, Schroeder S, et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Modern Pathology. 2004;17:1119–28. https://doi.org/10.1038/modpathol.3800160

Article  CAS  PubMed  Google Scholar 

Elder EE, Xu D, Höög A, et al. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Modern Pathology. 2003;16:246–55. https://doi.org/10.1097/01.MP.0000056982.07160.E3

Article  PubMed  Google Scholar 

Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery. 2008;143:759–68. https://doi.org/10.1016/j.surg.2008.02.007

Article  PubMed  Google Scholar 

Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med. 2018;7. https://doi.org/10.3390/jcm7090280

Kimura N, Shiga K, Kaneko K, et al. The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma. Endocr Pathol. 2020;31:95–100. https://doi.org/10.1007/s12022-020-09618-1

Article  CAS  PubMed  Google Scholar 

Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. American Journal of Surgical Pathology. 2014;38:13–22. https://doi.org/10.1097/PAS.0b013e3182a0218f

Article  PubMed  Google Scholar 

Erickson LA, Mete O. Immunohistochemistry in Diagnostic Parathyroid Pathology. Endocr Pathol. 2018;29:113–29.

Article  CAS  PubMed  Google Scholar 

Turchini J, Sioson L, Clarkson A, et al. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Endocr Pathol. 2020;31:150–5. https://doi.org/10.1007/s12022-020-09615-4

Article  PubMed  Google Scholar 

Mete O, Kefeli M, Çalışkan S, et al. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Modern Pathology. 2019;32:484–9. https://doi.org/10.1038/s41379-018-0167-7

Article  CAS  PubMed  Google Scholar 

Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33:115–54.

Article  CAS  PubMed